Trial Profile
An Open-label, Single-dose, Clinical Trial of 68Ga-DOTATATE (GalioMedix™) PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATATE (Primary)
- Indications Neuroendocrine tumours
- Focus Diagnostic use
- 05 Oct 2020 Status changed from recruiting to completed.
- 12 May 2015 New trial record